BLASUBCUTANEOUSINJECTION
Approved
Mar 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
CONEXXENCE (denosumab) by Fresenius Kabi is rank ligand blocking activity [moa]. Approved for osteoporosis, postmenopausal osteoporosis, bone metastases. First approved in 2025.
Drug data last refreshed 18h ago
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications (3)
Worked on CONEXXENCE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.